
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb has demonstrated strong growth metrics across its business segments, with contact lens market share increasing to 10%, reflecting a 40 basis points rise year-over-year. The surgical segment reported revenues of $231 million, a year-over-year increase of approximately 13%, bolstered by a 67% surge in premium intraocular lenses. Additionally, the consumer segment achieved revenues of $476 million in Q4, marking an 8% increase year-over-year and outpacing consensus estimates, underscoring the company’s robust performance and potential for continued market expansion.
Bears say
Bausch & Lomb is projected to experience flat to low-single digit revenue growth, leading to reduced operating margin improvement and diminished earnings per share (EPS) growth, which contribute to a negative financial outlook. Key operational risks include competition from lower-cost online contact lens providers, patent challenges, and external geopolitical factors such as the Russia-Ukraine conflict, all of which may hinder revenue growth and market share. Additionally, the company's forecasted EPS for 2025 and 2026 has been lowered, reflecting concerns over its under-scaled Surgical segment and a reliance on a lower-multiple prescription business, which justifies a discount to industry peers.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares